Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Change in Acquisitions & Divestments (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Change in Acquisitions & Divestments readings, the most recent being $30.0 million for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments rose 20.0% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.0 million through Dec 2025, down 32.1% year-over-year, with the annual reading at $107.0 million for FY2025, 32.1% down from the prior year.
  • Change in Acquisitions & Divestments hit $30.0 million in Q4 2025 for Terns Pharmaceuticals, up from $24.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $92.0 million in Q2 2023 and bottomed at $13.5 million in Q3 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $35.1 million, with a median of $30.0 million recorded in 2025.
  • The largest annual shift saw Change in Acquisitions & Divestments surged 316.83% in 2023 before it tumbled 54.12% in 2024.
  • Terns Pharmaceuticals' Change in Acquisitions & Divestments stood at $13.5 million in 2021, then surged by 148.14% to $33.5 million in 2022, then surged by 56.11% to $52.3 million in 2023, then crashed by 52.19% to $25.0 million in 2024, then grew by 20.0% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Change in Acquisitions & Divestments are $30.0 million (Q4 2025), $24.5 million (Q3 2025), and $25.5 million (Q2 2025).